Related Experiment Video

Updated: Aug 15, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Antiplatelet therapy in anticoagulated patients requiring coronary intervention

Dinesh Arab1, Bruce Lewis, Leslie Cho

  • 1Loyola University Medical Center, Maywood, Illinois, USA.

The Journal of Invasive Cardiology
|October 6, 2005
PubMed

Insights

Optimal antiplatelet therapy for patients needing long-term anticoagulation after percutaneous coronary intervention is undefined. Balancing bleeding and thrombosis risks requires individualized treatment decisions due to limited trial data.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Standard antiplatelet therapy (aspirin and clopidogrel) aims to prevent stent thrombosis post-percutaneous coronary intervention (PCI).
  • Optimal antiplatelet strategies for patients on long-term anticoagulation after PCI are not well-defined.
  • Combining antiplatelet drugs with anticoagulation (e.g., warfarin) increases bleeding risk, while withholding antiplatelets raises thrombosis risk.

Purpose of the Study:

  • To define the optimal antiplatelet regimen for patients requiring long-term anticoagulation undergoing PCI.
  • To review the risks associated with various antiplatelet regimens in this patient population.

Main Methods:

  • Systematic review and synthesis of English language literature.
  • Examination of risks for subacute stent thrombosis, thromboembolism, and bleeding complications.
  • Analysis of various antiplatelet regimens in conjunction with anticoagulation.

Main Results:

  • No randomized trials currently exist to definitively guide optimal antiplatelet therapy in this cohort.
  • The feasibility of conducting such trials may be limited.
  • Treatment decisions necessitate careful consideration of individual patient risks.

Conclusions:

  • Optimal antiplatelet therapy post-PCI in anticoagulated patients remains undefined.
  • Treatment must be individualized, balancing the risks of bleeding against the risks of stent thrombosis and thromboembolism.
  • Further research is needed, but trial feasibility is a concern.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...